Bill would reclassify donor pancreatic islets as organs, not drugs
In committeeH.R. 8018Latest action
Sponsor: Ralph Norman · Representative · SC
AIDecoded by AI · checked against the recordRead the official text
Official title: ISLET Act
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
The ISLET Act would regulate donor pancreatic islets like transplant organs instead of drugs or biological products.
35-second read · 4 questions answered below
What does this do?
The ISLET Act would classify human islets from deceased donors the same way whole organs like kidneys are classified, rather than as drugs, biological products, or human tissue products. HHS would have one year to update related regulations and must report to Congress on progress within six months.
Who does it affect?
This affects patients needing islet transplants (often people with severe type 1 diabetes), transplant doctors and hospitals, organ procurement organizations, and companies that process islets.
Why does it matter?
The reclassification would shift islets out of drug/biological product regulatory pathways into organ transplant rules, changing which approval processes apply to their use.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedMar 19, 2026
- House committeeYou are here · Mar 19, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the House Committee on Energy and Commerce.